Description
Background:
Iladatuzumab is a biosimilar that targets CD79B. CD79b is the B cell antigen receptor Ig beta chain (BCR-Ig beta), which associates with B cell antigen receptor Ig alpha chain to form a functional heterodimer that interacts with membrane immunoglobulin (mIg). The mIgM component binds antigen and the Ig alpha /I g beta heterodimer tranduces signals.
Intended Use:
For Estimation of Iladatuzumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!